Mette Holme Jung
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Mette Holme Jung has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Finn Gustafsson
Department of Cardiology Rigshospitalet Copenhagen Denmark
6 shared publications Soeren Boesgaard
Department of Cardiology, The Heart Center, University Hospital Rigshospitalet, Copenhagen, Denmark
3 shared publicationsStuart D. Russell
Department of Cardiology, Johns Hopkins Hospital, Baltimore, MD, USA
3 shared publicationsKaare Sander
B Cardiothoracic Surgery , The Heart Center, Rigshospitalet, Copenhagen University Hospital , Denmark
2 shared publicationsPeter Bo Hansen
C Cardiothoracic Anesthesia , The Heart Center, Rigshospitalet, Copenhagen University Hospital , Denmark
2 shared publicationsBrian Houston
Department of Cardiology, Johns Hopkins Hospital, Baltimore, MD, USA
1 shared publication
Latest Publications
- 1 January 2017
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 36 (1) , 36-41
Pump speed modulations and sub-maximal exercise tolerance in left ventricular assist device recipients: A double-blind, randomized trial
- 1 January 2017
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 36 (1) , 36-41
Pump speed modulations and sub-maximal exercise tolerance in left ventricular assist device recipients: A double-blind, randomized trial
- 27 June 2016
- Published by Elsevier in International Journal of Cardiology
- Vol. 220, 196-200
Neurohormonal activation and exercise tolerance in patients supported with a continuous-flow left ventricular assist device
- 27 June 2016
- Published by Elsevier in International Journal of Cardiology
- Vol. 220, 196-200
Neurohormonal activation and exercise tolerance in patients supported with a continuous-flow left ventricular assist device
- 1 May 2015
- Published by Wolters Kluwer Health in ASAIO Journal
- Vol. 61 (3) , 307-312
Relation Between Pressure and Volume Unloading During Ramp Testing in Patients Supported with a Continuous-Flow Left Ventricular Assist Device
Pulmonary capillary wedge pressure (PCWP) is the key to describing left ventricular (LV) unloading; however, the relation between pressure and the echocardiography-derived surrogate of LV volume (LV end-diastolic diameter [LVEDD]) as a function of pump speed (revolutions per minute [RPM]) in continuous-flow LV assist device (CF-LVAD) patients is unknown. In this study, the pressure–volume relation as a function of RPM during ramp testing was investigated by simultaneously measuring PCWP by Swan-Ganz catheter and LVEDD by echocardiography. The ramp protocol started at usual pump setting (ramp-base) and then went from 8,000 RPM (ramp-low) increasing by 400 RPM/5 minutes until reaching 12,000 RPM or suction/arrhythmic event (ramp-high). The study was finalized by a 25 Watt exercise test at two ramp steps. Ten patients with ramp-base of 9,300 ± 241 RPM (at which 3 of 10 had aortic valve opening) were examined. At ramp-low, ramp-base, and ramp-high, PCWP was 20 ± 4, 14 ± 4, and 7 ± 3 mm Hg (p < 0.001 for all comparisons) and LVEDD 6.6 ± 1.0, 6.7 ± 0.9, and 5.5 ± 1.7 cm (p < 0.05 for all comparisons but ramp-low versus ramp-base). Correlation between PCWP and LVEDD slopes; R2 = 0.53 (p = 0.02). In conclusion, PCWP as a function of RPM is weakly correlated with changes in LVEDD. Thus, LVEDD is not an accurate measure of unloading in CF-LVAD patients.
- 1 May 2015
- Published by Wolters Kluwer Health in ASAIO Journal
- Vol. 61 (3) , 307-312
Relation Between Pressure and Volume Unloading During Ramp Testing in Patients Supported with a Continuous-Flow Left Ventricular Assist Device
Pulmonary capillary wedge pressure (PCWP) is the key to describing left ventricular (LV) unloading; however, the relation between pressure and the echocardiography-derived surrogate of LV volume (LV end-diastolic diameter [LVEDD]) as a function of pump speed (revolutions per minute [RPM]) in continuous-flow LV assist device (CF-LVAD) patients is unknown. In this study, the pressure–volume relation as a function of RPM during ramp testing was investigated by simultaneously measuring PCWP by Swan-Ganz catheter and LVEDD by echocardiography. The ramp protocol started at usual pump setting (ramp-base) and then went from 8,000 RPM (ramp-low) increasing by 400 RPM/5 minutes until reaching 12,000 RPM or suction/arrhythmic event (ramp-high). The study was finalized by a 25 Watt exercise test at two ramp steps. Ten patients with ramp-base of 9,300 ± 241 RPM (at which 3 of 10 had aortic valve opening) were examined. At ramp-low, ramp-base, and ramp-high, PCWP was 20 ± 4, 14 ± 4, and 7 ± 3 mm Hg (p < 0.001 for all comparisons) and LVEDD 6.6 ± 1.0, 6.7 ± 0.9, and 5.5 ± 1.7 cm (p < 0.05 for all comparisons but ramp-low versus ramp-base). Correlation between PCWP and LVEDD slopes; R2 = 0.53 (p = 0.02). In conclusion, PCWP as a function of RPM is weakly correlated with changes in LVEDD. Thus, LVEDD is not an accurate measure of unloading in CF-LVAD patients.
- 1 April 2015
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 34 (4) , 489-496
Exercise in heart failure patients supported with a left ventricular assist device
- 1 April 2015
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 34 (4) , 489-496
Exercise in heart failure patients supported with a left ventricular assist device
- 1 January 2015
- Published by Medknow
- Vol. 49 (6) , 367-75
Outcomes and hospital admissions during long-term support with a HeartMate II.
Continuous-flow left ventricular assist devices like the HeartMate II (HMII) improves survival in severe heart failure but little is known about the incidence and causes of hospitalizations during long-term support which was evaluated in this study. Observational follow-up study comprising all patients who received a HMII at our institution either as bridge-to-transplantation (BTT) or destination therapy (DT). All patients were followed from HMII implantation to transplantation, device explantation, death, or May 2015. The HMII was implanted in 66(44 BTT, 22 DT) patients with a median (range) duration of support since implantation of 329(2-2707) days with 260(2-1080) days in the BTT group and 608(6-2707) days in the DT group. Thirty-day mortality was 12% and one-year survival 76%, comparable for DT and BTT. Among 56 (19 DT and 37 BTT) patients discharged alive with a HMII there were 161 hospital readmissions during a follow-up of 336(37-2682) days corresponding to a hospitalization rate of 1.3(0-19) per patient year and with a length of stay of 5(2-72) days per admission. Most frequent cause of readmission was infections (29%). A history of atrial fibrillation was the only independent factor associated with increased readmission rates. Our single-center study demonstrated encouraging survival following HMII implantation. Hospital readmissions were frequent, mostly of short duration, mainly due to infections and increased in patients with atrial fibrillation.
- 1 January 2015
- Published by Medknow
- Vol. 49 (6) , 367-75
Outcomes and hospital admissions during long-term support with a HeartMate II.
Continuous-flow left ventricular assist devices like the HeartMate II (HMII) improves survival in severe heart failure but little is known about the incidence and causes of hospitalizations during long-term support which was evaluated in this study. Observational follow-up study comprising all patients who received a HMII at our institution either as bridge-to-transplantation (BTT) or destination therapy (DT). All patients were followed from HMII implantation to transplantation, device explantation, death, or May 2015. The HMII was implanted in 66(44 BTT, 22 DT) patients with a median (range) duration of support since implantation of 329(2-2707) days with 260(2-1080) days in the BTT group and 608(6-2707) days in the DT group. Thirty-day mortality was 12% and one-year survival 76%, comparable for DT and BTT. Among 56 (19 DT and 37 BTT) patients discharged alive with a HMII there were 161 hospital readmissions during a follow-up of 336(37-2682) days corresponding to a hospitalization rate of 1.3(0-19) per patient year and with a length of stay of 5(2-72) days per admission. Most frequent cause of readmission was infections (29%). A history of atrial fibrillation was the only independent factor associated with increased readmission rates. Our single-center study demonstrated encouraging survival following HMII implantation. Hospital readmissions were frequent, mostly of short duration, mainly due to infections and increased in patients with atrial fibrillation.
- Open Access
- 15 October 2014
- Published by Oxford University Press (OUP) in European Journal of Heart Failure
- Vol. 16 (11) , 1257
Does Increased Oxygen Extraction Contribute to the Improvement of VO2peak Observed in Patients who Exercise with Increased LVAD Speed?: Reply
- 15 October 2014
- Published by Oxford University Press (OUP) in European Journal of Heart Failure
- Vol. 16 (11) , 1257
Open AccessDoes Increased Oxygen Extraction Contribute to the Improvement of VO2peak Observed in Patients who Exercise with Increased LVAD Speed?: Reply
- Open Access
- 8 January 2014
- Published by Oxford University Press (OUP) in European Journal of Heart Failure
- Vol. 16 (4) , 403-408
Effect of Increasing Pump Speed During Exercise on Peak Oxygen Uptake in Heart Failure Patients Supported with a Continuous-Flow Left Ventricular Assist Device. A Double-Blind Randomized Study
Aims Continuous‐flow left ventricular assist device (CF‐LVAD) implantation is associated with improved quality of life, but the effect on exercise capacity is less well documented. It is uncertain whether a fixed CF‐LVAD pump speed, which allows for sufficient circulatory support at rest, remains adequate during exercise. The aim of this study was to evaluate the effects of fixed versus incremental pump speed on peak oxygen uptake (peak VO2) during a maximal exercise test. Methods and results In CF‐LVAD (HeartMate II) patients exercise testing measuring peak oxygen uptake (VO2) was performed on an ergometer bike twice in one day: once with fixed pump speed (testfix) and once with incremental pump speed (testinc). The order of testfix and testinc in each patient was determined by randomization. During testinc pump speed was increased from the baseline value by 400 rpm/2 min. Fourteen patients (aged 23–69 years) were included with a mean support duration of 465 ± 483 days. Baseline CF‐LVAD speed was 9357 ± 238 rpm and during testinc speed was increased by a mean of 1486 ± 775 rpm. Mean peak VO2 was significantly higher in testinc compared with testfix (15.4 ± 5.9 mL/kg/min vs. 14.1 ± 6.3 mL/kg/min; P = 0.012), corresponding to a 9.2% increase. All exercise tests (n = 28) were adequately performed with RER > 1. Conclusion Increasing pump speed during exercise augments peak VO2 in patients supported with CF‐LVADs. An automatic speed‐change function in future generations of CF‐LVADs might improve functional capacity.
- 8 January 2014
- Published by Oxford University Press (OUP) in European Journal of Heart Failure
- Vol. 16 (4) , 403-408
Open AccessEffect of Increasing Pump Speed During Exercise on Peak Oxygen Uptake in Heart Failure Patients Supported with a Continuous-Flow Left Ventricular Assist Device. A Double-Blind Randomized Study
Aims Continuous‐flow left ventricular assist device (CF‐LVAD) implantation is associated with improved quality of life, but the effect on exercise capacity is less well documented. It is uncertain whether a fixed CF‐LVAD pump speed, which allows for sufficient circulatory support at rest, remains adequate during exercise. The aim of this study was to evaluate the effects of fixed versus incremental pump speed on peak oxygen uptake (peak VO2) during a maximal exercise test. Methods and results In CF‐LVAD (HeartMate II) patients exercise testing measuring peak oxygen uptake (VO2) was performed on an ergometer bike twice in one day: once with fixed pump speed (testfix) and once with incremental pump speed (testinc). The order of testfix and testinc in each patient was determined by randomization. During testinc pump speed was increased from the baseline value by 400 rpm/2 min. Fourteen patients (aged 23–69 years) were included with a mean support duration of 465 ± 483 days. Baseline CF‐LVAD speed was 9357 ± 238 rpm and during testinc speed was increased by a mean of 1486 ± 775 rpm. Mean peak VO2 was significantly higher in testinc compared with testfix (15.4 ± 5.9 mL/kg/min vs. 14.1 ± 6.3 mL/kg/min; P = 0.012), corresponding to a 9.2% increase. All exercise tests (n = 28) were adequately performed with RER > 1. Conclusion Increasing pump speed during exercise augments peak VO2 in patients supported with CF‐LVADs. An automatic speed‐change function in future generations of CF‐LVADs might improve functional capacity.